1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Cancer Peptides: From First-in-Class to Best-in-Class?

Cancer Peptides: From First-in-Class to Best-in-Class?

  • January 2013
  • -
  • Bioseeker
  • -
  • 1013 pages

This report gives you a new and unique way of stratifying and analyzing the global peptide pipeline in cancer towards personalized medicine and presents actionable analysis which allows you to discover:

* Where the competition is; Which targets, tumor types and companies are setting the path?

* What is first-in-class in the cancer peptide pipeline?

* Is First-in-Class the Best-in-Class?

* Indication expansion opportunities

* Drug repositioning opportunities

* Which pathways are targeted, by what and how?

* Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 171 peptide drugs in cancer from within the portfolio of 114 companies world-wide, from Ceased to Marketed. We have identified 132 drug targets, which we have organized into 109 drug target strategies and assessed them 62 tumor types. Our pipeline analysis has four levels:

1. Target Atlas: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.

2. First-in-Class to Best-in-Class: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.

3. Indication Selection: Shows the distribution and deployment of target strategies by cancer indications. The competitive level in each cancer indication is assessed.

4. Competive Landscape: Provides a cross-examination of each company’s entire pipeline on the basis of its defined drug target
strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.
Our Analysis includes:

* Head-to-head target competing analysis

* Significant drug target overlap analysis

* Cross-sectional R&D profiling of individual drug targets.

* Cross-over analysis of target strategies among different tumor types.

* Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company’s pipeline:
- Where are we?
- Where is our general and specific competition?
- What is the level of competition where we want to be?

* 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company’s interest in the peptide pipeline in cancer by:

* Better identifying benchmarking peers

* Providing rationale for in/out licensing decisions of drug candidates

* Performing proper drug due diligence

* Strategies for commercial planning

* Guiding Research & Development efforts

Table Of Contents

Cancer Peptides: From First-in-Class to Best-in-Class?
1 Executive Summary 3

2 About Cancer Highlights - A Module of the DevOnc Platform 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group's Oncology Team 6

3 Methodology 7
3.1 Cancer Highlights' Five Pillar Drug Assessment 7

4 Table of Contents 9
4.1 List of Figures 19
4.2 List of Tables 19

5 Introduction 27
5.1 The Scope of this Report 27
5.2 Definitions 30
5.3 Abbreviations 30

6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment 31
6.1 Drug Repositioning in Oncology 31
6.2 Introduction to Targets of Peptide Drugs in Cancer 32
6.2.1 Carboxy-lyase Activity Targets 37
6.2.2 Cell Adhesion Molecule Activity Targets 38
6.2.3 Chaperone Activity Targets 39
6.2.4 Chemokine Activity Targets 44
6.2.5 Cytokine Activity Targets 48
6.2.6 Cytoskeletal Protein Binding Targets 50
6.2.7 DNA Binding Targets 51
6.2.8 DNA Topoisomerase Activity Targets 52
6.2.9 DNA-directed DNA Polymerase Activity Targets 53
6.2.10 G-protein Coupled Receptor Activity Targets 54
6.2.11 Growth Factor Activity Targets 75
6.2.12 Heat Shock Protein Activity Targets 76
6.2.13 Hormone Activity Targets 77
6.2.14 Hydrolase Activity Targets 78
6.2.15 Kinase Activity Targets 79
6.2.16 Kinase Binding Targets 81
6.2.17 Kinase Regulator Activity Targets 83
6.2.18 Ligand-dependent Nuclear Receptor Activity Targets 84
6.2.19 Metallopeptidase Activity Targets 87
6.2.20 Molecular Function Unknown Targets 91
6.2.21 Oxidoreductase Activity Targets 97
6.2.22 Peptide Hormone Targets 98
6.2.23 Protease Inhibitor Activity Targets 100
6.2.24 Protein Binding Targets 101
6.2.25 Protein Serine/Threonine Kinase Activity Targets 102
6.2.26 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 111
6.2.27 Protein-tyrosine Kinase Activity Targets 112
6.2.28 Receptor Activity Targets 116
6.2.29 Receptor Binding Targets 139
6.2.30 Receptor Signaling Complex Scaffold Activity Targets 142
6.2.31 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 148
6.2.32 RNA Binding Targets 150
6.2.33 RNA-directed DNA Polymerase Activity Targets 151
6.2.34 Serine-type Peptidase Activity Targets 152
6.2.35 Signal Transducer Activity Targets 158
6.2.36 Structural Constituent of Cytoskeleton Targets 160
6.2.37 Structural Molecule Activity Targets 161
6.2.38 T Cell Receptor Activity Targets 162
6.2.39 Transcription Factor Activity Targets 163
6.2.40 Transcription Regulator Activity Targets 172
6.2.41 Transferase Activity Targets 173
6.2.42 Translation Regulator Activity Targets 174
6.2.43 Transmembrane Receptor Activity Targets 175
6.2.44 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 180
6.2.45 Ubiquitin-specific Protease Activity Targets 194
6.2.46 Other Targets 196
6.3 Mutation Profiles of Peptide Drug Targets in Oncology 199
6.3.1 Targets of Peptide Drugs in Cancer Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 199
6.4 Peptide Therapeutics is Stimulated by Available Structure Data on Targets 204
6.5 Target-Target Interactions among Identified Targets of Peptide Drugs in Cancer 207
6.6 Protein Expression Levels of Identified Targets of Peptide Drugs in Cancer 211
6.7 The Drug-Target Competitive Landscape 213
6.8 Pathway Assessment of Peptide Drugs in Cancer 217
6.8.1 Tools for Analysis of Cancer Pathways 218
6.8.2 Pathway Assessment 219

7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer 253
7.1 First-in-Class and Me-too of Registrered and Marketed Drugs 256
7.2 First-in-Class and Me-too in Phase III Clinical Development 257
7.3 First-in-Class and Me-too in Phase II Clinical Development 259
7.4 First-in-Class and Me-too in Phase I Clinical Development 261
7.5 First-in-Class and Me-too in Preclinical Development 263
7.6 Drug Target Strategies of Suspended or Terminated Peptide Drugs in Cancer 266

8 Is First-in-Class the Best-in-Class? 268
8.1.1 Marketed 271
8.1.2 Registered 280
8.1.3 Phase III 281
8.1.4 Phase II 294
8.1.5 Phase I 313
8.1.6 Preclinical 321
8.1.7 Suspended 352
8.1.8 Ceased 354

9 The Competition Through Close Mechanistic Approximation of Peptide Drugs in Cancer 388

10 Selecting Indication for Peptide Drugs in Oncology 391
10.1 Acromegaly 394
10.2 Acute Lymphocytic Leukemia 396
10.3 Acute Myelogenous Leukemia 397
10.4 Benign prostatic hyperplasia 399
10.5 Biliary Cancer 400
10.6 Bladder Cancer 401
10.7 Bone Cancer 402
10.8 Brain Cancer 403
10.9 Breast Cancer 405
10.10 Cancer (general) 407
10.11 Cancer Diagnosis 408
10.12 Carcinoid 409
10.13 Carcinoid syndrome 411
10.14 Cervical Cancer 415
10.15 Chronic Lymphocytic Leukemia 416
10.16 Chronic Myelogenous Leukemia 417
10.17 Colorectal Adenoma 418
10.18 Colorectal Cancer 419
10.19 Endometrial Cancer 421
10.20 Fallopian Tube Cancer 422
10.21 Gastrointestinal Cancer (general) 423
10.22 Gastrointestinal Stomach Cancer 424
10.23 Head and Neck Cancer 425
10.24 Hematological Cancer (general) 426
10.25 Hodgkin's Lymphoma 427
10.26 Leukemia (general) 428
10.27 Liver Cancer 429
10.28 Lung Cancer (general) 431
10.29 Lymphoma (general) 432
10.30 Melanoma 433
10.31 Mesothelioma 435
10.32 Myelodysplastic Syndrome 436
10.33 Myeloma 437
10.34 Neuroblastoma 439
10.35 Neuroendocrine Tumors (general) 440
10.36 Neuroendocrine Tumors (pancreatic) 442
10.37 non-Hodgkin's Lymphoma 443
10.38 Non-Small Cell Lung Cancer 444
10.39 Oral Cancer 446
10.40 Ovarian Cancer 447
10.41 Pancreatic Cancer 449
10.42 Peritoneal Cancer 451
10.43 Prostate Cancer 452
10.44 Radio/chemotherapy-induced Alopecia 455
10.45 Radio/chemotherapy-induced Anemia 456
10.46 Radio/chemotherapy-induced Bone Marrow Injury (general) 457
10.47 Radio/chemotherapy-induced GI Injury 458
10.48 Radio/chemotherapy-induced Injury (general) 459
10.49 Radio/chemotherapy-induced Mucositis 460
10.50 Radio/chemotherapy-induced Nausea and Vomiting 461
10.51 Radio/chemotherapy-induced Neutropenia 462
10.52 Renal Cancer 463
10.53 Sarcoma (general) 465
10.54 Skin Cancer (general) 466
10.55 Small Cell Lung Cancer 467
10.56 Soft Tissue Sarcoma 468
10.57 Solid Tumor 469
10.58 Squamous Cell Carcinoma 470
10.59 T-cell Lymphoma 471
10.60 Thyroid Cancer 472
10.61 Unspecified Tumor Type 473
10.62 Vaccine adjunct 475

11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator 476
11.1 Changes in the Competitive Landscape: MandA, Bankruptcy and Name Change 479
11.2 Company Facts and Ranking 481
11.3 Competitive Fall-Out Assessment 488
11.4 7TM Pharma 490
11.5 Abbott 493
11.6 Acceleron Pharma 500
11.7 AEterna Zentaris 505
11.8 Affymax 510
11.9 Agenus 516
11.10 Aileron Therapeutics 521
11.11 Allostera 524
11.12 Allosterix 527
11.13 Ambrilia Biopharma 531
11.14 Anchor Therapeutics 537
11.15 AngioChem 541
11.16 Angstrom Pharmaceuticals 546
11.17 AplaGen Biopharmaceuticals 550
11.18 ApopLogic Pharmaceuticals 553
11.19 Ardana 557
11.20 AstraZeneca 563
11.21 Attenuon 568
11.22 Baxter International 572
11.23 Biokine Therapeutics 577
11.24 Bristol-Myers Squibb 581
11.25 Camurus 584
11.26 CanBas 589
11.27 Cancer Advances 594
11.28 Cancer Innovations 598
11.29 Cancer Research Technology 602
11.30 CDG Therapeutics 609
11.31 Celecure 613
11.32 Celldex Therapeutics 617
11.33 Chemokine Therapeutics 621
11.34 Chiasma 626
11.35 Cleveland BioLabs 631
11.36 Clinuvel 634
11.37 Compugen 637
11.38 Curaxis 640
11.39 Cyclacel 645
11.40 Daiichi Sankyo 648
11.41 Debiopharm 651
11.42 Dendreon 656
11.43 Digna Biotech 661
11.44 Dongkook Pharm 664
11.45 Eli Lilly 669
11.46 Endo Pharmaceuticals 673
11.47 Enkam Pharmaceuticals 680
11.48 EntreMed 684
11.49 Esperance Pharmaceuticals 688
11.50 Formula Pharmaceuticals 695
11.51 Galena Biopharma 700
11.52 Generex 705
11.53 GENova Biotherapeutics 708
11.54 Genovax 711
11.55 GlaxoSmithKline 716
11.56 Glide Pharma 721
11.57 Gliknik 726
11.58 GP Pharm 730
11.59 Gryphon Therapeutics 738
11.60 Hoffmann-La Roche 742
11.61 ImmunoCellular Therapeutics 747
11.62 Immunotope 751
11.63 ImmuPharma 755
11.64 Innovive 760
11.65 Ipsen 765
11.66 ISA Pharmaceuticals 770
11.67 Johnson and Johnson 774
11.68 KAEL-GemVax 780
11.69 Karyon-CTT 785
11.70 Kirax 789
11.71 Lee's Pharmaceutical 792
11.72 Marillion Pharmaceuticals 796
11.73 MBiotec 801
11.74 Meda 804
11.75 Mediolanum 809
11.76 Merck KGaA 814
11.77 MolMed 818
11.78 Nektar Therapeutics 822
11.79 Nemod Biotherapeutics 827
11.80 Neurobiological Technologies 832
11.81 Nidus Laboratories 835
11.82 Non-industrial Sources 839
11.83 Novartis 847
11.84 NPS Pharmaceuticals 856
11.85 OncoTherapy Science 860
11.86 Oncothyreon 864
11.87 Pepscan Therapeutics 870
11.88 Peptagen 874
11.89 PepTx 877
11.90 PharmaGap 881
11.91 PharmaMar 885
11.92 Pharmexa 892
11.93 Protagonist 897
11.94 Q Chip 900
11.95 QLT 907
11.96 Raptor Pharmaceutical 912
11.97 Receptor BioLogix 916
11.98 Sanofi 921
11.99 Sarepta Therapeutics 925
11.100 SciClone Pharmaceuticals 929
11.101 Serometrix 933
11.102 Shire 937
11.103 Soligenix 942
11.104 Spectrum Pharmaceuticals 947
11.105 Tactic Pharma 950
11.106 Thallion Pharmaceuticals 954
11.107 Therion Biologics 958
11.108 Theryte 961
11.109 Titan Pharmaceuticals 965
11.110 Unigene 968
11.111 United Biomedical 973
11.112 Vaxil BioTherapeutics 977
11.113 Vaxon Biotech 982
11.114 Wilex 987
11.115 Xigen 992
11.116 Zelos Therapeutics 995
11.117 Zensun 998

12 Disclaimer 1002

13 Drug Index 1003

14 Company Index 1009



1.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Peptide Drugs in Cancer 210
Figure 2: The Drug-Target Competitive Landscape of Peptide Drugs in Cancer - Large Cluster 214
Figure 3: The Drug-Target Competitive Landscape Peptide Drugs in Cancer - Smaller Clusters 215
Figure 4: Head-to-Head Targeting Competitive Landscape of Peptide Drugs in Cancer 216
Figure 5: Number of Companies per Ranking Level 483



1.2 List of Tables

Table 1: Cancer Highlights' Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Peptide Drug Pipeline in Oncology by Stage of Development 27
Table 3: Head to Head Target Competition among Peptide Drugs 27
Table 4: Overview of Drug Target Strategy Themes 32
Table 5: Ceased Targets of Peptide Drugs in Cancer 33
Table 6: Official Gene Symbol to Target Profle 34
Table 7: Mutation Frequencies of Peptide Drug Targets 200
Table 8: Identity of Drug Targets with Available Biological Structures 204
Table 9: Number of Target-Target Interactions among Targets of Peptide Drugs in Cancer 208
Table 10: Available Protein Expression Profiles of Peptide Drug Targets 211
Table 11: Pathway Summary 219
Table 12: Drug Targets without any Identified Assigned Pathways 219
Table 13: Pathway Profiles According to BioCarta of Peptide Drug Targets in Oncology 221
Table 14: Pathway Profiles According to KEGG of Peptide Drug Targets in Oncology 232
Table 15: Pathway Profiles According to NetPath of Peptide Drug Targets in Oncology 249
Table 16: First-in-Class Analysis of Drug Target Strategies 254
Table 17: Top Competitive Target Strategies of Peptide Drugs in Cancer 254
Table 18: First-in-Class and Me-too of Registered and Marketed Peptide Drugs for the Treatment of Cancer 256
Table 19: The Competition Through Close Mechanistic Approximation Between Peptide Drugs in Cancer Being Marketed 256
Table 20: First-in-Class and Me-too of Peptide Drugs in Phase III Clinical Development for the Treatment of Cancer 257
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Peptide Drugs in Cancer 258
Table 22: First-in-Class and Me-too of Peptide Drugs in Phase II Clinical Development for the Treatment of Cancer 259
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Peptide Drugs in Cancer 260
Table 24: First-in-Class and Me-too of Peptide Drugs in Phase I Clinical Development for the Treatment of Cancer 261
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Peptide Drugs in Cancer 262
Table 26: First-in-Class and Me-too of Peptide Drugs Preclinical Development for the Treatment of Cancer 263
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Peptide Drugs in Cancer 264
Table 28: Target Strategies of Suspended or Terminated Peptide Drugs in Cancer 266
Table 29: Finding Competitive Profile for Best-in-Class Consideration 268
Table 30: The Competition Through Close Mechanistic Approximation Among Peptide Drugs in Cancer 388
Table 31 Competitive Summary by Cancer Indication of Peptide Drugs 392
Table 32: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Acromegaly 394
Table 33: The Competition through Close Mechanistic Approximation between Acromegaly Drugs 395
Table 34: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Acute Lymphocytic Leukemia 396
Table 35: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Acute Myelogenous Leukemia 397
Table 36: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 397
Table 37: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Benign Prostatic Hyperplasia 399
Table 38: The Competition through Close Mechanistic Approximation between Benign Prostatic Hyperplasia Drugs 399
Table 39: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Biliary Cancer 400
Table 40: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Bladder Cancer 401
Table 41: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Bone Cancer 402
Table 42: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Brain Cancer 403
Table 43: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 404
Table 44: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Breast Cancer 405
Table 45: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 406
Table 46: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Cancer (general) 407
Table 47: Target Strategy Development Profiles of Peptide Drugs Cancer Diagnosis 408
Table 48: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Carcinoid 409
Table 49: The Competition through Close Mechanistic Approximation between Carcinoid Drugs 409
Table 50: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Carcinoid syndrome 411
Table 51: The Competition through Close Mechanistic Approximation between Carcinoid Syndrome Drugs 414
Table 52: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Cervical Cancer 415
Table 53: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chronic Lymphocytic Leukemia 416
Table 54: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chronic Myelogenous Leukemia 417
Table 55: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Colorectal Adenoma 418
Table 56: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Colorectal Cancer 419
Table 57: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 420
Table 58: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Endometrial Cancer 421
Table 59: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Fallopian Tube Cancer 422
Table 60: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Gastrointestinal Cancer (general) 423
Table 61: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 423
Table 62: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Gastrointestinal Stomach Cancer 424
Table 63: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Head and Neck Cancer 425
Table 64: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Hematological Cancer (general) 426
Table 65: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Hodgkin's Lymphoma 427
Table 66: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Leukemia (general) 428
Table 67: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Liver Cancer 429
Table 68: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 430
Table 69: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Lung Cancer (general) 431
Table 70: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Lymphoma (general) 432
Table 71: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Melanoma 433
Table 72: The Competition through Close Mechanistic Approximation between Melanoma Drugs 434
Table 73: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Mesothelioma 435
Table 74: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 435
Table 75: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Myelodysplastic Syndrome 436
Table 76: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Myeloma 437
Table 77: The Competition through Close Mechanistic Approximation between Myeloma Drugs 437
Table 78: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Neuroblastoma 439
Table 79: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Neuroendocrine Tumors (general) 440
Table 80: The Competition through Close Mechanistic Approximation between Neuroendocrine Tumors (general) Drugs 441
Table 81: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Neuroendocrine Tumors (pancreatic) 442
Table 82: Target Strategy Development Profiles of Peptide Drugs for the Treatment of non-Hodgkin's Lymphoma 443
Table 83: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Non-Small Cell Lung Cancer 444
Table 84: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 445
Table 85: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Oral Cancer 446
Table 86: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Ovarian Cancer 447
Table 87: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 448
Table 88: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Pancreatic Cancer 449
Table 89: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 450
Table 90: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Peritoneal Cancer 451
Table 91: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Prostate Cancer 452
Table 92: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 453
Table 93: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Alopecia 455
Table 94: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Anemia 456
Table 95: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Bone Marrow Injury (general) 457
Table 96: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced GI Injury 458
Table 97: The Competition through Close Mechanistic Approximation between Radio/chemotherapy-induced GI Injury Drugs 458
Table 98: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Injury (general) 459
Table 99: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Mucositis 460
Table 100: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Nausea and Vomiting 461
Table 101: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Neutropenia 462
Table 102: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Renal Cancer 463
Table 103: The Competition through Close Mechanistic Approximation between Neuroendocrine Tumors (general) Drugs 464
Table 104: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Sarcoma (general) 465
Table 105: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Skin Cancer (general) 466
Table 106: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Small Cell Lung Cancer 467
Table 107: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Soft Tissue Sarcoma 468
Table 108: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Solid Tumor 469
Table 109: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Squamous Cell Carcinoma 470
Table 110: Target Strategy Development Profiles of Peptide Drugs for the Treatment of T-cell Lymphoma 471
Table 111: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Thyroid Cancer 472
Table 112: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Unspecified Tumor Type 473
Table 113: The Competition through Close Mechanistic Approximation between Unspecified Tumor Drugs 474
Table 114: Target Strategy Development Profiles of Peptide Drugs as Vaccine adjuncts for the Treatment of Cancer 475
Table 115: Competitive Summary by Investigator of Peptide Drug Development in Cancer 476
Table 116: Summary Table of Corporate Changes in the Competitive Landscape of Cancer Peptide Drug Development 479
Table 117: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 482
Table 118: Example of a Competitive Fall-Out Table (Targeting GNRHR Modified) 488
Table 119: 7TM Pharma's Included Peptide Drugs in Oncology and Competitive Fall-Out 491
Table 120: Abbott's Included Peptide Drugs in Oncology and Competitive Fall-Out 496
Table 121: Acceleron Pharma's Included Peptide Drugs in Oncology and Competitive Fall-Out 502
Table 122: AEterna Zentaris' Included Peptide Drugs in Oncology and Competitive Fall-Out 507
Table 123: Affymax's Included Peptide Drugs in Oncology and Competitive Fall-Out 512
Table 124: Agenus' Included Peptide Drugs in Oncology and Competitive Fall-Out 518
Table 125: Aileron Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 522
Table 126: Allostera's Included Peptide Drugs in Oncology and Competitive Fall-Out 525
Table 127: Allosterix's Included Peptide Drugs in Oncology and Competitive Fall-Out 528
Table 128: Ambrilia Biopharma's Included Peptide Drugs in Oncology and Competitive Fall-Out 533
Table 129: Anchor Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 538
Table 130: AngioChem's Included Peptide Drugs in Oncology and Competitive Fall-Out 543
Table 131: Angstrom Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 547
Table 132: AplaGen Biopharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 551
Table 133: ApopLogic Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 554
Table 134: Ardana's Included Peptide Drugs in Oncology and Competitive Fall-Out 559
Table 135: AstraZeneca's Included Peptide Drugs in Oncology and Competitive Fall-Out 565
Table 136: Attenuon's Included Peptide Drugs in Oncology and Competitive Fall-Out 569
Table 137: Baxter International's Included Peptide Drugs in Oncology and Competitive Fall-Out 574
Table 138: Biokine Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 578
Table 139: Bristol-Myers Squibb's Included Peptide Drugs in Oncology and Competitive Fall-Out 582
Table 140: Camurus' Included Peptide Drugs in Oncology and Competitive Fall-Out 586
Table 141: CanBas' Included Peptide Drugs in Oncology and Competitive Fall-Out 591
Table 142: Cancer Advances' Included Peptide Drugs in Oncology and Competitive Fall-Out 595
Table 143: Cancer Innovations' Included Peptide Drugs in Oncology and Competitive Fall-Out 599
Table 144: Cancer Research Technology's Included Peptide Drugs in Oncology and Competitive Fall-Out 604
Table 145: CDG Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 610
Table 146: Celecure's Included Peptide Drugs in Oncology and Competitive Fall-Out 614
Table 147: Celldex Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 618
Table 148: Chemokine Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 623
Table 149: Chiasma's Included Peptide Drugs in Oncology and Competitive Fall-Out 628
Table 150: Cleveland BioLabs' Included Peptide Drugs in Oncology and Competitive Fall-Out 632
Table 151: Clinuvel's Included Peptide Drugs in Oncology and Competitive Fall-Out 635
Table 152: Compugen's Included Peptide Drugs in Oncology and Competitive Fall-Out 638
Table 153: Curaxis' Included Peptide Drugs in Oncology and Competitive Fall-Out 642
Table 154: Cyclacel's Included Peptide Drugs in Oncology and Competitive Fall-Out 646
Table 155: Daiichi Sankyo's Included Peptide Drugs in Oncology and Competitive Fall-Out 649
Table 156: Debiopharm's Included Peptide Drugs in Oncology and Competitive Fall-Out 653
Table 157: Dendreon's Included Peptide Drugs in Oncology and Competitive Fall-Out 658
Table 158: Digna Biotech's Included Peptide Drugs in Oncology and Competitive Fall-Out 662
Table 159: Dongkook Pharm's Included Peptide Drugs in Oncology and Competitive Fall-Out 666
Table 160: Eli Lilly's Included Peptide Drugs in Oncology and Competitive Fall-Out 670
Table 161: Endo Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 676
Table 162: Enkam Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 681
Table 163: EntreMed's Included Peptide Drugs in Oncology and Competitive Fall-Out 685
Table 164: Esperance Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 690
Table 165: Formula Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 697
Table 166: Galena Biopharma's Included Peptide Drugs in Oncology and Competitive Fall-Out 702
Table 167: Generex's Included Peptide Drugs in Oncology and Competitive Fall-Out 706
Table 168: GENova Biotherapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 709
Table 169: Genovax's Included Peptide Drugs in Oncology and Competitive Fall-Out 713
Table 170: GlaxoSmithKline's Included Peptide Drugs in Oncology and Competitive Fall-Out 718
Table 171: Glide Pharma's Included Peptide Drugs in Oncology and Competitive Fall-Out 723
Table 172: Gliknik's Included Peptide Drugs in Oncology and Competitive Fall-Out 727
Table 173: GP Pharm's Included Peptide Drugs in Oncology and Competitive Fall-Out 733
Table 174: Gryphon Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 739
Table 175: Hoffmann-La Roche's Included Peptide Drugs in Oncology and Competitive Fall-Out 744
Table 176: ImmunoCellular Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 748
Table 177: Immunotope's Included Peptide Drugs in Oncology and Competitive Fall-Out 752
Table 178: ImmuPharma's Included Peptide Drugs in Oncology and Competitive Fall-Out 757
Table 179: Innovive's Included Peptide Drugs in Oncology and Competitive Fall-Out 762
Table 180: Ipsen's Included Peptide Drugs in Oncology and Competitive Fall-Out 767
Table 181: ISA Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 771
Table 182: Johnson and Johnson's Included Peptide Drugs in Oncology and Competitive Fall-Out 776
Table 183: KAEL-GemVax's Included Peptide Drugs in Oncology and Competitive Fall-Out 782
Table 184: Karyon-CTT's Included Peptide Drugs in Oncology and Competitive Fall-Out 786
Table 185: Kirax's Included Peptide Drugs in Oncology and Competitive Fall-Out 790
Table 186: Lee's Pharmaceutical's Included Peptide Drugs in Oncology and Competitive Fall-Out 793
Table 187: Marillion Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 798
Table 188: MBiotec's Included Peptide Drugs in Oncology and Competitive Fall-Out 802
Table 189: Meda's Included Peptide Drugs in Oncology and Competitive Fall-Out 806
Table 190: Mediolanum's Included Peptide Drugs in Oncology and Competitive Fall-Out 811
Table 191: Merck KGaA's Included Peptide Drugs in Oncology and Competitive Fall-Out 815
Table 192: MolMed's Included Peptide Drugs in Oncology and Competitive Fall-Out 819
Table 193: Nektar Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 824
Table 194: Nemod Biotherapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 829
Table 195: Neurobiological Technologies' Included Peptide Drugs in Oncology and Competitive Fall-Out 833
Table 196: Nidus Laboratories' Included Peptide Drugs in Oncology and Competitive Fall-Out 836
Table 197: Non-industrial Source's Included Peptide Drugs in Oncology and Competitive Fall-Out 841
Table 198: Novartis' Included Peptide Drugs in Oncology and Competitive Fall-Out 849
Table 199: NPS Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 857
Table 200: OncoTherapy Science's Included Peptide Drugs in Oncology and Competitive Fall-Out 861
Table 201: Oncothyreon's Included Peptide Drugs in Oncology and Competitive Fall-Out 866
Table 202: Pepscan Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 871
Table 203: Peptagen's Included Peptide Drugs in Oncology and Competitive Fall-Out 875
Table 204: PepTx's Included Peptide Drugs in Oncology and Competitive Fall-Out 878
Table 205: PharmaGap's Included Peptide Drugs in Oncology and Competitive Fall-Out 882
Table 206: PharmaMar's Included Peptide Drugs in Oncology and Competitive Fall-Out 887
Table 207: Pharmexa's Included Peptide Drugs in Oncology and Competitive Fall-Out 894
Table 208: Protagonist's Included Peptide Drugs in Oncology and Competitive Fall-Out 898
Table 209: Q Chip's Included Peptide Drugs in Oncology and Competitive Fall-Out 903
Table 210: QLT's Included Peptide Drugs in Oncology and Competitive Fall-Out 909
Table 211: Raptor Pharmaceutical's Included Peptide Drugs in Oncology and Competitive Fall-Out 913
Table 212: Receptor BioLogix's Included Peptide Drugs in Oncology and Competitive Fall-Out 918
Table 213: Sanofi's Included Peptide Drugs in Oncology and Competitive Fall-Out 922
Table 214: Sarepta Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 926
Table 215: SciClone Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 930
Table 216: Serometrix's Included Peptide Drugs in Oncology and Competitive Fall-Out 934
Table 217: Shire's Included Peptide Drugs in Oncology and Competitive Fall-Out 939
Table 218: Soligenix's Included Peptide Drugs in Oncology and Competitive Fall-Out 944
Table 219: Spectrum Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 948
Table 220: Tactic Pharma's Included Peptide Drugs in Oncology and Competitive Fall-Out 951
Table 221: Thallion Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 955
Table 222: Therion Biologics' Included Peptide Drugs in Oncology and Competitive Fall-Out 959
Table 223: Theryte's Included Peptide Drugs in Oncology and Competitive Fall-Out 962
Table 224: Titan Pharmaceuticals' Included Peptide Drugs in Oncology and Competitive Fall-Out 966
Table 225: Unigene's Included Peptide Drugs in Oncology and Competitive Fall-Out 970
Table 226: United Biomedical's Included Peptide Drugs in Oncology and Competitive Fall-Out 974
Table 227: Vaxil BioTherapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 979
Table 228: Vaxon Biotech's Included Peptide Drugs in Oncology and Competitive Fall-Out 984
Table 229: Wilex's Included Peptide Drugs in Oncology and Competitive Fall-Out 989
Table 230: Xigen's Included Peptide Drugs in Oncology and Competitive Fall-Out 993
Table 231: Zelos Therapeutics' Included Peptide Drugs in Oncology and Competitive Fall-Out 996
Table 232: Zensun's Included Peptide Drugs in Oncology and Competitive Fall-Out 999

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
TCR/CAR-T Therapies in Oncology: Analytical Tool

TCR/CAR-T Therapies in Oncology: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Tumor Ablation Market by Technology, Mode of Treatment, Application - Global Forecast 2021

Tumor Ablation Market by Technology, Mode of Treatment, Application - Global Forecast 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global tumor ablation market is estimated to register a high CAGR of 12.5% during 2016-2021, and is expected to be valued at ~USD 580.1 million in 2021. Although mature markets (North America and Europe) ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.